Tat-induced crispr/endonuclease-based gene editing
US-2018073019-A1 · Mar 15, 2018 · US
Multiplexed genome editing
US11064684B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11064684-B2 |
| Application number | US-201916531351-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 5, 2019 |
| Priority date | Oct 8, 2015 |
| Publication date | Jul 20, 2021 |
| Grant date | Jul 20, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A method of modulating some or all copies of a gene in a cell is provided including introducing into a cell one or more ribonucleic acid (RNA) sequences that comprise a portion that is complementary to all or a portion of each of the one or more target nucleic acid sequences, and a nucleic acid sequence that encodes a Cas protein and maintaining the cells under conditions in which the Cas protein is expressed and the Cas protein binds and modulates the one or more target nucleic acid sequences in the cell.
First claim
Opening claim text (preview).
What is claimed is: 1. A genetically engineered porcine cell in which at least 97% of the porcine endogenous retrovirus (“PERV”) pol genes comprise a genetically engineered genomic indel. 2. The genetically engineered porcine cell of claim 1 , wherein 100% of the PERV pol genes comprise a genetically engineered genomic indel. 3. The genetically engineered porcine cell of claim 1 , wherein the genetically engineered porcine cell exhibits at least a 1000-fold reduction in PERV transmission as evidenced by co-culturing a human cell with the genetically engineered porcine cell as compared to co-culturing a human cell with a wild-type porcine cell. 4. The genetically engineered porcine cell of claim 3 , wherein the human cell is HEK293. 5. The genetically engineered porcine cell of claim 1 , wherein the genetically engineered genomic indel is observed by sequencing. 6. The genetically engineered porcine cell of claim 1 , wherein the genetically engineered porcine cell contains intact PERV gag and/or env genes. 7. The genetically engineered porcine cell of claim 1 , wherein the genetically engineered porcine cell is from an embryo. 8. The genetically engineered porcine cell of claim 1 , wherein the genetically engineered porcine cell is a stem cell, zygote, or germ line cell. 9. The genetically engineered porcine cell of claim 1 , wherein the genetically engineered porcine cell is an embryonic stem cell or pluripotent stem cell. 10. The genetically engineered porcine cell of claim 1 , wherein the genetically engineered porcine cell is a somatic cell. 11. A progeny cell derived from the genetically engineered porcine cell of claim 1 . 12. A composition comprising a plurality of the progeny cell of claim 11 .
Assignees
Inventors
Classifications
by genetic engineering · CPC title
- C12N15/8509Primary
for producing genetically modified animals, e.g. transgenic · CPC title
against retroviridae, e.g. HIV · CPC title
with deoxyribosyl as saccharide radical · CPC title
Animal producing cells or organs for transplantation · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11064684B2 cover?
- A method of modulating some or all copies of a gene in a cell is provided including introducing into a cell one or more ribonucleic acid (RNA) sequences that comprise a portion that is complementary to all or a portion of each of the one or more target nucleic acid sequences, and a nucleic acid sequence that encodes a Cas protein and maintaining the cells under conditions in which the Cas prote…
- Who is the assignee on this patent?
- Harvard College
- What technology area does this patent fall under?
- Primary CPC classification C12N15/8509. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).